AR092860A1 - Formulacion oftalmica y metodo para mejorar la presbicia - Google Patents
Formulacion oftalmica y metodo para mejorar la presbiciaInfo
- Publication number
- AR092860A1 AR092860A1 ARP130102572A ARP130102572A AR092860A1 AR 092860 A1 AR092860 A1 AR 092860A1 AR P130102572 A ARP130102572 A AR P130102572A AR P130102572 A ARP130102572 A AR P130102572A AR 092860 A1 AR092860 A1 AR 092860A1
- Authority
- AR
- Argentina
- Prior art keywords
- ophthalmic formulation
- formulation according
- pharmaceutically acceptable
- acceptable salt
- amount
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 13
- 239000000203 mixture Substances 0.000 title abstract 13
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 5
- 229960001802 phenylephrine Drugs 0.000 abstract 3
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 abstract 3
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical group C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 abstract 2
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 abstract 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 2
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 abstract 2
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 239000000674 adrenergic antagonist Substances 0.000 abstract 2
- 230000001387 anti-histamine Effects 0.000 abstract 2
- 239000000739 antihistaminic agent Substances 0.000 abstract 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 abstract 2
- 229960001416 pilocarpine Drugs 0.000 abstract 2
- 201000010041 presbyopia Diseases 0.000 abstract 2
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical group C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 abstract 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 abstract 1
- -1 ethylephrine Chemical compound 0.000 abstract 1
- 229960001929 meloxicam Drugs 0.000 abstract 1
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 abstract 1
- 229960001002 nepafenac Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 1
- 229960001528 oxymetazoline Drugs 0.000 abstract 1
- 239000000734 parasympathomimetic agent Substances 0.000 abstract 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 abstract 1
- 229960000395 phenylpropanolamine Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 229960001262 tramazoline Drugs 0.000 abstract 1
- QQJLHRRUATVHED-UHFFFAOYSA-N tramazoline Chemical compound N1CCN=C1NC1=CC=CC2=C1CCCC2 QQJLHRRUATVHED-UHFFFAOYSA-N 0.000 abstract 1
- 239000005526 vasoconstrictor agent Substances 0.000 abstract 1
- 230000004304 visual acuity Effects 0.000 abstract 1
- 229960000833 xylometazoline Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Formulación oftálmica que comprende una cantidad eficaz de un agente parasimpatomimético que es la pilocarpina o una sal farmacéuticamente aceptable de ésta, así como de uno o más agonistas o antagonistas adrenérgicos a1. La formulación oftálmica puede ser útil para tratar aquellos trastornos que afectan de manera adversa la agudeza visual de un paciente, como es el caso de la presbicia. Método para usar una formulación oftálmica como la que se ha descripto en el tratamiento o la mejora de los síntomas de la presbicia. Reivindicación 2: La formulación oftálmica de acuerdo con la reivindicación 1, caracterizada porque los uno o más agonistas o antagonistas adrenérgicos a1 se seleccionan del grupo que consiste en la fenilefrina, la fenilpropanolamina, la etilefrina, la oximetazolina, la xilometazolina, la tramazolina y las sales farmacéuticamente aceptables de éstas. Reivindicación 3: La formulación oftálmica de acuerdo con la reivindicación 1, caracterizada porque comprende un agonista adrenérgico a1 que es la fenilefrina o una sal farmacéuticamente aceptable de ésta. Reivindicación 4: La formulación oftálmica de acuerdo con la reivindicación 3, caracterizada porque la fenilefrina está presente en una cantidad de entre aproximadamente 0,5% y aproximadamente 3% en peso. Reivindicación 6: La formulación oftálmica de acuerdo con cualquiera de las reivindicaciones 1 - 5, caracterizada porque la pilocarpina está presente en una cantidad de entre aproximadamente 0,1% y aproximadamente 0,7% en peso. Reivindicación 8: La formulación oftálmica de acuerdo con la reivindicación 7, caracterizada porque el agente vasoconstrictor es la nafazolina o una sal farmacéuticamente aceptable de ésta. Reivindicación 9: La formulación oftálmica de acuerdo con la reivindicación 7, caracterizada porque también comprende un antihistamínico. Reivindicación 11: La formulación oftálmica de acuerdo con la reivindicación 9, caracterizada porque el antihistamínico es la feniramina o una sal farmacéuticamente aceptable de ésta. Reivindicación 12: La formulación oftálmica de acuerdo con la reivindicación 11, caracterizada porque la feniramina está presente en una cantidad de entre aproximadamente 0,03% y aproximadamente 0,09% en peso. Reivindicación 15: La formulación oftálmica de acuerdo con la reivindicación 13, caracterizada porque la droga antiinflamatoria no esteroidal se selecciona del grupo que consiste en el nepafenac y el meloxicam.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/553,615 US10507245B2 (en) | 2012-07-19 | 2012-07-19 | Ophthalmic formulation and method for ameliorating presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR092860A1 true AR092860A1 (es) | 2015-05-06 |
Family
ID=48917698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102572A AR092860A1 (es) | 2012-07-19 | 2013-07-19 | Formulacion oftalmica y metodo para mejorar la presbicia |
| ARP210100987A AR121843A2 (es) | 2012-07-19 | 2021-04-14 | Formulación oftálmica y método para mejorar la presbicia |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210100987A AR121843A2 (es) | 2012-07-19 | 2021-04-14 | Formulación oftálmica y método para mejorar la presbicia |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10507245B2 (es) |
| EP (1) | EP2874660B1 (es) |
| CN (2) | CN104717981A (es) |
| AR (2) | AR092860A1 (es) |
| BR (1) | BR112015001158B1 (es) |
| CO (1) | CO7250451A2 (es) |
| DK (1) | DK2874660T3 (es) |
| ES (1) | ES2719250T3 (es) |
| HR (1) | HRP20190627T1 (es) |
| MX (1) | MX351230B (es) |
| PL (1) | PL2874660T3 (es) |
| PT (1) | PT2874660T (es) |
| RU (1) | RU2657514C2 (es) |
| TR (1) | TR201905683T4 (es) |
| WO (1) | WO2014015183A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2715296T3 (es) | 2011-09-20 | 2019-06-03 | Allergan Inc | Composiciones y métodos para tratar presbicia, hipermetropía leve y astigmatismo irregular |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| EP3104851A1 (en) * | 2014-02-11 | 2016-12-21 | Orasis Pharmaceuticals Ltd. | Pharmacological ophthalmic composition for use in the correction of presbyopia and its administration |
| CN104856990A (zh) * | 2015-05-07 | 2015-08-26 | 武汉武药科技有限公司 | 去氧肾上腺素酮咯酸溶液及制备方法 |
| US20190000808A1 (en) * | 2015-07-13 | 2019-01-03 | Allergan, Inc. | Composition and methods for the treatment of blephopharoptosis |
| CH711969A2 (it) * | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composizione per il trattamento della presbiopia. |
| PT3500255T (pt) * | 2016-08-19 | 2023-01-10 | Orasis Pharmaceuticals Ltd | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| BR112020015436A2 (pt) * | 2018-02-05 | 2020-12-22 | Cellix Bio Private Limited | Composição farmacêutica, mistura física e uso de uma composição |
| WO2019204401A1 (en) * | 2018-04-19 | 2019-10-24 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| MX2020011301A (es) | 2018-04-24 | 2021-01-29 | Allergan Inc | Uso de clorhidrato de pilocarpina para el tratamiento de afecciones oculares. |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| US20210205273A1 (en) * | 2018-08-21 | 2021-07-08 | Allergan, Inc. | The use of alpha-2-adrenergic receptor agonists for improving vision |
| EP3870170A4 (en) | 2018-10-26 | 2022-07-20 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PRESBYOPIA, MYDRIASIS AND OTHER EYE DISEASES |
| US11071724B2 (en) * | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| CN114585365A (zh) * | 2019-06-10 | 2022-06-03 | 视觉治疗股份有限公司 | 在假晶状体患者中使用拟副交感神经药物单独或与一种或多种α激动剂组合以产生多焦点 |
| MX2020012116A (es) * | 2020-11-12 | 2022-08-09 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia. |
| CN115368310A (zh) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| CN116350790A (zh) * | 2021-12-28 | 2023-06-30 | 沈阳兴齐眼药股份有限公司 | 组合物及其在制备用于治疗老花眼的药物中的用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474751A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
| DK335086A (da) | 1985-08-05 | 1987-02-06 | Michele Testa | Kemiske sammensaetninger og farmaceutiske praeparater til topisk brug indeholdende mindst en af de kemiske sammensaetninger i en terapeutiskvirksom maengde |
| US4902696A (en) * | 1987-10-08 | 1990-02-20 | Hoechst-Roussel Pharmaceuticals, Inc. | Synergistic intraocular pressure lowering combinations |
| US5192780A (en) * | 1989-12-18 | 1993-03-09 | Alcon Laboratories, Inc. | Methods using antiallergics and antihistamines |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| US5459133A (en) | 1992-06-05 | 1995-10-17 | Telor Ophthalmic Pharmaceuticals, Inc. | Methods and products for treating presbyopia |
| HU220864B1 (en) * | 1993-04-16 | 2002-06-29 | Wakamoto Pharma Co Ltd | Reversible, thermally gelling water-base medicinal compositions |
| US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
| IT1306135B1 (it) * | 1999-04-26 | 2001-05-30 | Farmigea Spa | Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto. |
| US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
| WO2004058289A1 (en) | 2002-12-20 | 2004-07-15 | Chakshu Research, Inc. | Ophthalmic formulation for the prevention and treatment of ocular conditions |
| US20060166879A1 (en) | 2002-12-20 | 2006-07-27 | Chakshu Research Inc | Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders |
| US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
| US20060172972A1 (en) | 2002-12-20 | 2006-08-03 | Chakshu Research Inc | Formulation and method for administration of ophthalmologically active agents |
| US7252662B2 (en) | 2004-11-02 | 2007-08-07 | Lenticular Research Group Llc | Apparatus and processes for preventing or delaying one or more symptoms of presbyopia |
| ATE439863T1 (de) | 2006-12-18 | 2009-09-15 | Jorge Luis Benozzi | Ophthalmische zusammensetzungen von parasympathischen stimulantia und entzündungshemmer zur verwendung bei der behandlung von presbyopie |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| TNSN08110A1 (en) | 2008-03-11 | 2009-07-14 | Rekik Raouf Dr | Drug delivery to the anterior and posterior segment of the eye from drops |
| TWI542338B (zh) | 2008-05-07 | 2016-07-21 | 壯生和壯生視覺關懷公司 | 用於活性劑之控制釋放的眼用裝置 |
| WO2010125416A1 (en) | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
| US8299079B2 (en) * | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US20100298335A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
| EP2482788B1 (en) | 2009-10-02 | 2022-12-14 | Journey Medical Corporation | Topical tetracycline compositions |
| US20120245505A1 (en) | 2009-12-16 | 2012-09-27 | Robinson Michael R | Intracameral devices for sustained delivery |
| US20110301555A1 (en) | 2010-06-03 | 2011-12-08 | Gonzalez-Zugasti Javier P | Porous matrix drug core for lacrimal insert device |
| US20120003296A1 (en) | 2010-07-01 | 2012-01-05 | Shantha Totada R | New methods of treating dry eye syndrome |
| ES2715296T3 (es) | 2011-09-20 | 2019-06-03 | Allergan Inc | Composiciones y métodos para tratar presbicia, hipermetropía leve y astigmatismo irregular |
-
2012
- 2012-07-19 US US13/553,615 patent/US10507245B2/en active Active
-
2013
- 2013-07-18 EP EP13745508.5A patent/EP2874660B1/en active Active
- 2013-07-18 CN CN201380043978.XA patent/CN104717981A/zh active Pending
- 2013-07-18 RU RU2015102531A patent/RU2657514C2/ru active
- 2013-07-18 PL PL13745508T patent/PL2874660T3/pl unknown
- 2013-07-18 WO PCT/US2013/051153 patent/WO2014015183A1/en active Application Filing
- 2013-07-18 DK DK13745508.5T patent/DK2874660T3/en active
- 2013-07-18 ES ES13745508T patent/ES2719250T3/es active Active
- 2013-07-18 TR TR2019/05683T patent/TR201905683T4/tr unknown
- 2013-07-18 BR BR112015001158-6A patent/BR112015001158B1/pt active IP Right Grant
- 2013-07-18 PT PT13745508T patent/PT2874660T/pt unknown
- 2013-07-18 MX MX2015000806A patent/MX351230B/es active IP Right Grant
- 2013-07-18 CN CN202110595122.XA patent/CN113425715A/zh active Pending
- 2013-07-19 AR ARP130102572A patent/AR092860A1/es not_active Application Discontinuation
-
2015
- 2015-01-28 CO CO15017205A patent/CO7250451A2/es unknown
-
2019
- 2019-04-01 HR HRP20190627TT patent/HRP20190627T1/hr unknown
- 2019-12-03 US US16/701,602 patent/US20200237916A1/en not_active Abandoned
-
2021
- 2021-04-14 AR ARP210100987A patent/AR121843A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200237916A1 (en) | 2020-07-30 |
| PL2874660T3 (pl) | 2019-07-31 |
| BR112015001158B1 (pt) | 2020-12-15 |
| DK2874660T3 (en) | 2019-04-15 |
| CO7250451A2 (es) | 2015-04-30 |
| RU2657514C2 (ru) | 2018-06-14 |
| MX351230B (es) | 2017-10-06 |
| HRP20190627T1 (hr) | 2019-06-14 |
| ES2719250T3 (es) | 2019-07-09 |
| PT2874660T (pt) | 2019-05-14 |
| CN104717981A (zh) | 2015-06-17 |
| EP2874660B1 (en) | 2019-01-23 |
| MX2015000806A (es) | 2015-08-10 |
| US20140024642A1 (en) | 2014-01-23 |
| WO2014015183A1 (en) | 2014-01-23 |
| AR121843A2 (es) | 2022-07-13 |
| US10507245B2 (en) | 2019-12-17 |
| CN113425715A (zh) | 2021-09-24 |
| EP2874660A1 (en) | 2015-05-27 |
| BR112015001158A2 (pt) | 2017-06-27 |
| RU2015102531A (ru) | 2016-09-10 |
| TR201905683T4 (tr) | 2019-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR092860A1 (es) | Formulacion oftalmica y metodo para mejorar la presbicia | |
| DOP2019000168A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2017002527A1 (es) | Uso de agonistas de receptor de péptido formilo 2 para tratar enfermedades inflamatorias oculares. (divisional de solicitud n°2485-2015). | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| BR112018015273A2 (pt) | derivados de benzimidazol como moduladores de ror-gama | |
| BR112014026493A2 (pt) | derivados de imidazotiadiazol como inibidores do receptor ativado por protease 4 (par4) para tratar a agregação de plaqueta | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| BR112014026643A2 (pt) | derivados de imidazotiadiazol e imidazopirazina como inibidores de receptor 4 ativado por protease (par4) para o tratamento de agregação de plaqueta | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
| CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| AR093247A1 (es) | Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo | |
| AR085668A1 (es) | Terapias combinadas para malignidades hematologicas | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112014031091A2 (pt) | Derivados de piperidina para agonista de gpr119 | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
| BR112013033831A2 (pt) | composição farmacêutica oftalmológica tópica que contém regorafenib | |
| CL2013003646A1 (es) | Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros. | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| EA201890684A1 (ru) | Производные фториндола в качестве положительных аллостерических модуляторов мускаринового рецептора m1 | |
| BR112015023694A2 (pt) | entrega craniana de fármacos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |